<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800172</url>
  </required_header>
  <id_info>
    <org_study_id>34538/3/21</org_study_id>
    <nct_id>NCT04800172</nct_id>
  </id_info>
  <brief_title>The Possible Effects of Roflumilast on Obesity Related Disorders</brief_title>
  <official_title>The Possible Effects of Roflumilast on Obesity Related Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the possible effects of roflumilast on weight, glucose and lipid metabolism,&#xD;
      insulin resistance, oxidative stress and inflammatory process in prediabetic obese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in patients body weight</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>substracting pre-treatment from post-treatment values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood glucose</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>using glucose oxidase method for assessment of blood glucose and substracting pre-treatment from post-treatment values.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma insulin level</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>substracting pre-treatment from post-treatment values of plasma insulin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HOMA-IR index</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>HOMA-IR will be calculated for all patients at baseline and 3 months later.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood lipid levels</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>blood lipid levels will be measured at baseline and 3 months after treatment including total cholesterol, triglycerides, HDL-C and LDL-C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in TNF-alfa serum level</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>substracting pre-treatment from post-treatment values of TNF-alfa.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in malondialdehyde serum level (MDA)</measure>
    <time_frame>baseline and 3 months later</time_frame>
    <description>substracting pre-treatment from post-treatment values of MDA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Obesity</condition>
  <condition>PreDiabetes</condition>
  <arm_group>
    <arm_group_label>Roflumilast arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Roflumilast</intervention_name>
    <description>administration of roflumilast 500 mcg tablet once daily for 3 months.</description>
    <arm_group_label>Roflumilast arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>administration of placebo tablet once daily for 3 months.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prediabetic patients (fasting blood glucose between 100 mg/dl and 125 mg/dl or HbA1C&#xD;
             within the range 5.7% and 6.4%).&#xD;
&#xD;
          2. Obese subjects (BMI ≥30 kg/m2 and &lt;40 kg/m2).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with morbid obesity (BMI &gt; 40 kg/m2).&#xD;
&#xD;
          2. Patients already on weight lowering agents or weight loss program.&#xD;
&#xD;
          3. History or current diagnosis of major depressive disorder or other psychiatric&#xD;
             disorders that in the opinion of the investigator would make participation unsafe for&#xD;
             the participant.&#xD;
&#xD;
          4. Moderate to severe liver disease (Child-Pugh B or C), renal disease, thyroid disease,&#xD;
             cardiovascular disease, peripheral vascular disease or coagulopathy.&#xD;
&#xD;
          5. Women will be excluded from our study if they are pregnant, breastfeeding, currently&#xD;
             on contraceptive pills or if they plan to become pregnant prior to the end of the&#xD;
             study.&#xD;
&#xD;
          6. Patients on medications that can interfere with glucose or lipid metabolism (e.g.&#xD;
             hypoglycemic agents, corticosteroids, anti-hyperlipidemics, non-selective β-blockers&#xD;
             thiazides, etc.) and subjects with organic causes of obesity.&#xD;
&#xD;
          7. Diabetic patients and patients with any inflammatory disease.&#xD;
&#xD;
          8. Smokers.&#xD;
&#xD;
          9. Patients on cytochrome P450 inducers (e.g. rifampicin, phenobarbital, carbamazepine,&#xD;
             phenytoin, etc.)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara M Zayed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sara M Zayed</last_name>
    <phone>00201019724428</phone>
    <email>sonsonmg85@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sara Mohammad Zayed</name>
      <address>
        <city>Tanta</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara M Zayed</last_name>
      <phone>00201019724428</phone>
      <email>sonsonmg85@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>November 6, 2021</last_update_submitted>
  <last_update_submitted_qc>November 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sara Mohammed Zayed</investigator_full_name>
    <investigator_title>Pharm D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data of outcomes and other research but not personal data are intended to be published in application to scientific journals</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

